Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -48% Improvement Relative Risk c19hcq.com Lyashchenko et al. HCQ for COVID-19 LATE TREATMENT Favors HCQ Favors control
Lyashchenko, 3,256 patient HCQ late treatment study: 48% higher mortality [p<0.0001] https://c19p.org/lyashchenko
copied to clipboard
Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID‐19 patients in New York City
Lyashchenko et al., British Journal of Clinical Pharmacology, doi:10.1111/bcp.15489
12 Aug 2022    Source   PDF   Share   Tweet
Retrospective very late stage hospitalized patients in New York during the first wave, showing no significant relationship between HCQ levels and outcomes. Authors note that the patients with data were the sickest patients.
risk of death, 47.7% higher, RR 1.48, p < 0.001, treatment 389 of 1,419 (27.4%), control 341 of 1,837 (18.6%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
Lyashchenko et al., 12 Aug 2022, retrospective, USA, peer-reviewed, 6 authors, study period March 2020 - June 2020, average treatment delay 9.5 days.
Contact: mty@cumc.columbia.edu, sc2752@cumc.columbia.edu.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit